A Study of Vedolizumab in People With Ulcerative Colitis and Crohn's Disease
Status:
Not yet recruiting
Trial end date:
2023-10-31
Target enrollment:
Participant gender:
Summary
Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system.
In this study, people with ulcerative colitis or Crohn's disease will be treated with
vedolizumab. The main aim of the study is to check for side effects from vedolizumab.
At the first visit, the study doctor will check who can take part. Participants will receive
vedolizumab slowly through a vein (infusion). Participants will regularly visit the clinic
for up to 46 weeks for more infusions of Vedolizumab. During these visits, the study doctor
will check if there are any side effects from this treatment.
Participants will visit the clinic for a final check-up up to 16 weeks after their final
infusion of Vedolizumab. Clinic staff will arrange a phone call 6 months after their final
infusion of Vedolizumab for a further check-up.